Open AccessGilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3 ‐Mutated AML
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13652
Subject(s) - medicine , azacitidine , myeloid leukemia , oncology , induction therapy , chemotherapy , dna methylation , gene expression , gene , biochemistry , chemistry
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed FLT3 ‐mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients.